A Double-Blind, Placebo-Controlled, Crossover Study of Magnesium Supplementation in Patients with XMEN Disease
Chauvin SD, Price S, Zou J, Hunsberger S, Brofferio A, Matthews H, Similuk M, Rosenzweig SD, Su HC, Cohen JI, Lenardo MJ, Ravell JC
Journal of clinical immunology · 14 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas, más trabajo en animales o laboratorio
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Gobierno
- National Institutes of Health
- Gobierno
- National Institute of General Medical Sciences
- Gobierno
- National Institute of Allergy and Infectious Diseases
- Gobierno
- Office of Extramural Research, National Institutes of Health
- Gobierno
- NHLBI Division of Intramural Research
- Gobierno
- NIGMS NIH HHS
- Gobierno
- office of extramural research, national institutes of health
- Gobierno
- national institute of allergy and infectious diseases
- Subvenciones
- Office of Extramural Research, National Institutes of Health (T32 GM007170); National Institute of General Medical Sciences (T32GM007170); National Institutes of Health (T32GM007170)
Según 9 financiadores declarados.
Publicación
- Publicado
- 2021-10-16 · J Clin Immunol · vol. 42 · número 1 · págs. 108–118
- Editorial
- Springer Science+Business Media
- Citado
- 19 citas · más que el 79% de estudios similares · 1.3× el promedio de su campo
- Referencias
- 23 trabajos
- Acceso
- Acceso abierto (copia en repositorio)
- Áreas de investigación
- Immunodeficiency and Autoimmune Disorders · Magnesium in Health and Disease · Cytomegalovirus and herpesvirus research
- Palabras clave
- magnesium supplementation, magnesium L-threonate, magnesium sulfate, Epstein-Barr virus infection, NKG2D, CD8+ T cells, natural killer cells, primary immunodeficiency, EBV viremia
- MeSH
- cd8-positive t-lymphocytes, humans, herpesvirus 4, human, epstein-barr virus infections, neoplasms, magnesium, cation transport proteins, cross-over studies, dietary supplements, x-linked combined immunodeficiency diseases
12 autores
- Samuel D. Chauvin🇺🇸National Institutes of Health; National Institute of Allergy and Infectious Diseases; University of Pennsylvania
- Susan M Price🇺🇸National Institutes of Health; National Institute of Allergy and Infectious Diseases
- Juan Zou🇺🇸National Institutes of Health; National Institute of Allergy and Infectious Diseases
- Sally Hunsberger🇺🇸National Institute of Allergy and Infectious Diseases
- Alessandra Brofferio🇺🇸National Heart, Lung, and Blood Institute
- Helen F Matthews🇺🇸National Institutes of Health; National Institute of Allergy and Infectious Diseases
- Morgan N. Similuk🇺🇸National Institutes of Health; National Institute of Allergy and Infectious Diseases
- Sergio D. Rosenzweig🇺🇸National Institutes of Health; National Institutes of Health Clinical Center
- Helen C. Su🇺🇸National Institutes of Health; National Institute of Allergy and Infectious Diseases
- Jeffrey I. Cohen🇺🇸National Institutes of Health; National Institute of Allergy and Infectious Diseases
- Michael J. Lenardo🇺🇸 · autor de correspondenciaNational Institutes of Health; National Institute of Allergy and Infectious Diseases
- Juan C. Ravell🇺🇸 · autor de correspondenciaNational Institutes of Health; Hackensack University Medical Center; National Institute of Allergy and Infectious Diseases; Hackensack Meridian School of Medicine
Resumen
El texto original del estudio, en el idioma en que se publicó.
X-linked MAGT1 deficiency with increased susceptibility to Epstein-Barr virus (EBV) infection and N-linked glycosylation defect (XMEN) disease is an inborn error of immunity caused by loss-of-function mutations in the magnesium transporter 1 (MAGT1) gene. The original studies of XMEN patients focused on impaired magnesium regulation, leading to decreased EBV-cytotoxicity and the loss of surface expression of the activating receptor "natural killer group 2D" (NKG2D) on CD8+ T cells and NK cells. In vitro studies showed that supraphysiological supplementation of magnesium rescued these defects. Observational studies in 2 patients suggested oral magnesium supplementation could decrease EBV viremia. Hence, we performed a randomized, double-blind, placebo-controlled, crossover study in 2 parts. In part 1, patients received either oral magnesium L-threonate (MLT) or placebo for 12 weeks followed by 12 weeks of the other treatment. Part 2 began with 3 days of high-dose intravenous (IV) magnesium sulfate (MgSO4) followed by open-label MLT for 24 weeks. One EBV-infected and 3 EBV-naïve patients completed part 1. One EBV-naïve patient was removed from part 2 of the study due to asymptomatic elevation of liver enzymes during IV MgSO4. No change in EBV or NKG2D status was observed. In vitro magnesium supplementation experiments in cells from 14 XMEN patients failed to significantly rescue NKG2D expression and the clinical trial was stopped. Although small, this study indicates magnesium supplementation is unlikely to be an effective therapeutic option in XMEN disease.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.